294 related articles for article (PubMed ID: 32043022)
1. Targeting the Mitochondria in Heart Failure: A Translational Perspective.
Sabbah HN
JACC Basic Transl Sci; 2020 Jan; 5(1):88-106. PubMed ID: 32043022
[TBL] [Abstract][Full Text] [Related]
2. Inefficient Batteries in Heart Failure: Metabolic Bottlenecks Disrupting the Mitochondrial Ecosystem.
Schwartz B; Gjini P; Gopal DM; Fetterman JL
JACC Basic Transl Sci; 2022 Nov; 7(11):1161-1179. PubMed ID: 36687274
[TBL] [Abstract][Full Text] [Related]
3. Mitochondrial Morphology, Dynamics, and Function in Human Pressure Overload or Ischemic Heart Disease With Preserved or Reduced Ejection Fraction.
Chaanine AH; Joyce LD; Stulak JM; Maltais S; Joyce DL; Dearani JA; Klaus K; Nair KS; Hajjar RJ; Redfield MM
Circ Heart Fail; 2019 Feb; 12(2):e005131. PubMed ID: 30744415
[TBL] [Abstract][Full Text] [Related]
4. Targeting mitochondrial dysfunction in the treatment of heart failure.
Sabbah HN
Expert Rev Cardiovasc Ther; 2016 Dec; 14(12):1305-1313. PubMed ID: 27758146
[TBL] [Abstract][Full Text] [Related]
5. Abnormalities of Mitochondrial Dynamics in the Failing Heart: Normalization Following Long-Term Therapy with Elamipretide.
Sabbah HN; Gupta RC; Singh-Gupta V; Zhang K; Lanfear DE
Cardiovasc Drugs Ther; 2018 Aug; 32(4):319-328. PubMed ID: 29951944
[TBL] [Abstract][Full Text] [Related]
6. Study protocol, randomized controlled trial: reducing symptom burden in patients with heart failure with preserved ejection fraction using ubiquinol and/or D-ribose.
Pierce JD; Mahoney DE; Hiebert JB; Thimmesch AR; Diaz FJ; Smith C; Shen Q; Mudaranthakam DP; Clancy RL
BMC Cardiovasc Disord; 2018 Apr; 18(1):57. PubMed ID: 29606104
[TBL] [Abstract][Full Text] [Related]
7. Chronic Therapy With Elamipretide (MTP-131), a Novel Mitochondria-Targeting Peptide, Improves Left Ventricular and Mitochondrial Function in Dogs With Advanced Heart Failure.
Sabbah HN; Gupta RC; Kohli S; Wang M; Hachem S; Zhang K
Circ Heart Fail; 2016 Feb; 9(2):e002206. PubMed ID: 26839394
[TBL] [Abstract][Full Text] [Related]
8. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation.
Paulus WJ; Tschöpe C
J Am Coll Cardiol; 2013 Jul; 62(4):263-71. PubMed ID: 23684677
[TBL] [Abstract][Full Text] [Related]
9. Energetic myocardial metabolism and oxidative stress: let's make them our friends in the fight against heart failure.
Scolletta S; Biagioli B
Biomed Pharmacother; 2010 Mar; 64(3):203-7. PubMed ID: 19954925
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of mitochondrial permeability transition pores by cyclosporine A improves cytochrome C oxidase function and increases rate of ATP synthesis in failing cardiomyocytes.
Sharov VG; Todor AV; Imai M; Sabbah HN
Heart Fail Rev; 2005 Dec; 10(4):305-10. PubMed ID: 16583179
[TBL] [Abstract][Full Text] [Related]
11. Neuregulin-1 attenuates mitochondrial dysfunction in a rat model of heart failure.
Guo YF; Zhang XX; Liu Y; Duan HY; Jie BZ; Wu XS
Chin Med J (Engl); 2012 Mar; 125(5):807-14. PubMed ID: 22490579
[TBL] [Abstract][Full Text] [Related]
12. Impact of the renin-angiotensin system on cardiac energy metabolism in heart failure.
Mori J; Zhang L; Oudit GY; Lopaschuk GD
J Mol Cell Cardiol; 2013 Oct; 63():98-106. PubMed ID: 23886814
[TBL] [Abstract][Full Text] [Related]
13. Fatigability, Exercise Intolerance, and Abnormal Skeletal Muscle Energetics in Heart Failure.
Weiss K; Schär M; Panjrath GS; Zhang Y; Sharma K; Bottomley PA; Golozar A; Steinberg A; Gerstenblith G; Russell SD; Weiss RG
Circ Heart Fail; 2017 Jul; 10(7):. PubMed ID: 28705910
[TBL] [Abstract][Full Text] [Related]
14. Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction.
Voors AA; Shah SJ; Bax JJ; Butler J; Gheorghiade M; Hernandez AF; Kitzman DW; McMurray JJV; Wirtz AB; Lanius V; van der Laan M; Solomon SD
Eur J Heart Fail; 2018 Nov; 20(11):1601-1610. PubMed ID: 30225882
[TBL] [Abstract][Full Text] [Related]
15. Skeletal Muscle Alterations Are Exacerbated in Heart Failure With Reduced Compared With Preserved Ejection Fraction: Mediated by Circulating Cytokines?
Seiler M; Bowen TS; Rolim N; Dieterlen MT; Werner S; Hoshi T; Fischer T; Mangner N; Linke A; Schuler G; Halle M; Wisloff U; Adams V
Circ Heart Fail; 2016 Sep; 9(9):. PubMed ID: 27609832
[TBL] [Abstract][Full Text] [Related]
16. Heart failure progression and mortality in atrial fibrillation patients with preserved or reduced left ventricular ejection fraction.
Slee A; Saad M; Saksena S
J Interv Card Electrophysiol; 2019 Sep; 55(3):325-331. PubMed ID: 30887281
[TBL] [Abstract][Full Text] [Related]
17. Posttranslational modifications and dysfunction of mitochondrial enzymes in human heart failure.
Sheeran FL; Pepe S
Am J Physiol Endocrinol Metab; 2016 Aug; 311(2):E449-60. PubMed ID: 27406740
[TBL] [Abstract][Full Text] [Related]
18. Mitochondrial ROS Drive Sudden Cardiac Death and Chronic Proteome Remodeling in Heart Failure.
Dey S; DeMazumder D; Sidor A; Foster DB; O'Rourke B
Circ Res; 2018 Jul; 123(3):356-371. PubMed ID: 29898892
[TBL] [Abstract][Full Text] [Related]
19. Mitochondrial Bioenergetics and Dysfunction in Failing Heart.
Sheeran FL; Pepe S
Adv Exp Med Biol; 2017; 982():65-80. PubMed ID: 28551782
[TBL] [Abstract][Full Text] [Related]
20. Mitochondrial dysfunction as an arrhythmogenic substrate: a translational proof-of-concept study in patients with metabolic syndrome in whom post-operative atrial fibrillation develops.
Montaigne D; Marechal X; Lefebvre P; Modine T; Fayad G; Dehondt H; Hurt C; Coisne A; Koussa M; Remy-Jouet I; Zerimech F; Boulanger E; Lacroix D; Staels B; Neviere R
J Am Coll Cardiol; 2013 Oct; 62(16):1466-73. PubMed ID: 23644086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
